Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 64Neoplasms 45Colorectal Neoplasms 30Uterine Cervical Neoplasms 29Carcinoma, Hepatocellular 23Stomach Neoplasms 19Prostatic Neoplasms 19Carcinoma, Non-Small-Cell Lung 19Ovarian Neoplasms 17Lung Neoplasms 15Esophageal Neoplasms 13Pancreatic Neoplasms 12Multiple Myeloma 12Motor Activity 10Endometrial Neoplasms 10Urinary Bladder Neoplasms 9Colonic Neoplasms 9Recurrence 8Rectal Neoplasms 8Lymphoma, Follicular 8Melanoma 7Lymphoma 7Liver Neoplasms 7Hematologic Neoplasms 7Carcinoma, Ovarian Epithelial 7Triple Negative Breast Neoplasms 6Sleep Initiation and Maintenance Disorders 6Sarcopenia 6Neuroendocrine Tumors 6Leukemia 6

Interventions

ivarmacitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Patients With Advanced Solid Tumors Who Discontinued Treatment Due to irAE × 1 year × Clear all
NCT07313202 2025-12-31

Ivarmacitinib in Advanced Solid Tumors: A Prospective, Two-Cohort, Two-Phase Exploratory Study in Patients Discontinued Due to Immune Intolerance

Fujian Cancer Hospital

Phase 2 Not yet recruiting
72 enrolled
Other solid neoplasm

Patients With Advanced Solid Tumors Who Discontinued Treatment Due to irAE

Data powered by HemOnc (CC BY 4.0) Colophon âš¡